Boston, Massachusetts 02114


This study is an 8-week, randomized, double-blind, placebo-controlled trial of intranasal insulin as an adjunctive therapy, with a 4-week follow-up, in 60 non-diabetic schizophrenia subjects to examine insulin's effect on psychopathology and cognition. In addition, the study will examine insulin's effects on weight, food intake, resting energy expenditure, and body composition.

Study summary:

The specific aims include: Primary aims 1. Examine the efficacy of intranasal regular insulin (40 IU 4 times per day) in improving cognitive deficits in patients with schizophrenia. 2. Examine the efficacy of intranasal regular insulin in improving negative symptoms and positive symptoms of schizophrenia. Secondary aims 1. Examine intranasal insulin's effects on weight, food intake and resting energy expenditure. 2. Examine intranasal insulin's effects on body composition, waist circumference, and waist/hip ratio.


Inclusion Criteria: 1. Age 18-65 years. 2. Diagnosis of schizophrenia, any subtype or schizoaffective disorder, any subtype. 3. Stable dose of the current antipsychotic drug for at least one month. 4. Well established compliance with outpatient treatment per treating clinician's judgement. 5. Able to complete the cognitive assessment battery (must be English speaking). 6. Female subjects will be eligible to participate in the study if they are of non-childbearing potential or of child-bearing potential and willing to practice appropriate birth control methods (complete abstinence from sexual intercourse, female sterilization, sterilization of male partner, implants of levonorgestrel, injectable progestogen, oral contraceptives, intrauterine devices, or double barrier methods of contraception using spermicide with either a condom or diaphragm) during the study. Exclusion Criteria: 1. Inability to provide informed consent. 2. Current substance abuse. 3. Psychiatrically unstable per treating clinician's judgement. 4. Significant medical illnesses including uncontrolled hypertension, diabetes, seizure. disorder, severe cardiovascular, cerebrovascular, pulmonary, or thyroid diseases. 5. Pregnancy or breastfeeding.



Primary Contact:

Principal Investigator
Xiaoduo Fan, M.D.
Massachusetts General Hospital

Karina Tsatourian, Ph.D.
Phone: 617-912-7837

Backup Contact:

Ju Hyung Park, BA
Phone: 617-912-7848

Location Contact:

Boston, Massachusetts 02114
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.